Moderna (MRNA) shares jumped more than 10% to lead S&P 500 gainers Tuesday, a day after the first bird-flu death was reported in the U.S. The biotech company is developing a vaccine for H5N1.
On Monday, the Centers for Disease Control and Prevention (CDC) said that it was "saddened by Louisiana's report that a person previously hospitalized with severe avian influenza A (H5N1) illness [had] passed away." The agency added that it was "not unexpected because of the known potential for infection with these viruses to cause severe illness and death."
As of Monday, there had "been 66 confirmed human cases of H5N1 bird flu in the United States since 2024 and 67 since 2022," the CDC added.
Moderna shares were up 12% at $47.50 in early-afternoon trading Tuesday. Despite the gain, the stock has lost more than half of its value over the past year and is well off its all-time high of nearly $500 in August 2021, during the height of the COVID-19 pandemic.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。